Transdermal patch medication delivery systems and pediatric poisonings, 2002-2006

Clinical Pediatrics

Volumn 47, Issue 7, 2008, Pages 659-663

  Parekh, Dina ^a   Miller, Michael A ^a,b,c   Borys, Doug ^b   Patel, Paresh R ^a   Levsky, Marc E ^a  

^a CARL R DARNALL ARMY MEDICAL CENTER   (United States)

^b Central Texas Poison Center   (United States)

^c TRIPLER ARMY MEDICAL CENTER   (United States)

Author keywords

Patch; Pediatric; Poisoning; Transdermal

Indexed keywords

ANESTHETIC AGENT; CAMPHOR; CLONIDINE; ESTROGEN; GLYCERYL TRINITRATE; LIDOCAINE; MENTHOL; METHYLPHENIDATE; NICOTINE; OPIATE; SALICYLIC ACID; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; AUTONOMIC DYSFUNCTION; BRADYCARDIA; CHILD HEALTH; COMA; DRUG ABUSE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG FATALITY; DRUG INTOXICATION; DRUG MEGADOSE; DRUG MISUSE; DRUG OVERDOSE; DRUG SURVEILLANCE PROGRAM; FEMALE; FEVER; HEALTH HAZARD; HUMAN; HYPERACTIVITY; HYPERTENSION; HYPERVENTILATION; HYPOTENSION; LETHARGY; MALE; MEDICATION ERROR; MENTAL DISEASE; METABOLIC ACIDOSIS; METHEMOGLOBINEMIA; MICTURITION DISORDER; MIOSIS; NAUSEA; POISON CENTER; PRESCRIPTION; REFERENCE DATABASE; RESPIRATION DEPRESSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SUICIDE ATTEMPT; SWEAT GLAND DISEASE; TACHYCARDIA; TINNITUS; TRANSDERMAL PATCH; VOMITING; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; CHILD; FEMALE; HUMANS; MALE; NONPRESCRIPTION DRUGS; POISONING; RETROSPECTIVE STUDIES; TEXAS;

EID: 48449097597     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922808315211     Document Type: Article

References (21)

1. Schneider NG, Koury MA, Cortner C., et al. Preferences among four combination nicotine treatments [published online ahead of print August 1, 2006]. Psychopharmacology (Berl). 2006 ; 187: 476-485.
2. Winblad B., Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007 ; 22: 485-491.
3. Priano L., Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly [Review]. Drugs Aging. 2006 ; 23: 357-375.
4. Alternative routes of drug administration-advantages and disadvantages (subject review). American Academy of Pediatrics. Committee on Drugs. Pediatrics. 1997 ; 100: 143-152.
5. Nitti VW, Sanders S., Staskin DR, et al. Transdermal delivery of drugs for urologic applications: Basic principles and applications. Urology. 2006 ; 4: 657-664.
6. Dixit N., Bali V., Baboota S., Ahuja A., Ali J. Iontophoresis: an approach for controlled drug delivery: a review. Curr Drug Deliv. 2007 ; 4: 1-10.
7. Karande P., Jain A., Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol. 2004 ; 22: 192-197.
8. Wilkosz MF, Bogner RH Transdermal drug delivery. Part 1: Current status. US Pharm. 2003 ; 28: 4. http://www.uspharmacist.com/index.asp?show=article_page= 8_1061.htm. Accessed August 30, 2007.
9. Carter KA Heat-associated increase in transdermal fentanyl absorption. Am J Health Syst Pharm. 2003 ; 60: 191-192.
10. Watson WA, Litovitz TL, Klein-Schwartz W., et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2004 ; 22: 335-404.
11. Schneiders W., Rollow A., Rammelt S., et al. Risk-inducing activities leading to injuries in a child and adolescent population of Germany. J Trauma. 2007 ; 62: 996-1003.
12. Lee M., Phillips J. FDA safety page. Transdermal patches: high risk for error? Drug Topics. 2002 ; 1: 54-55. htpp://www.fda.gov/cder/drug/MedErrors/ transdermal.pdf. Accessed August 12, 2007.
13. Schneiders W., Rollow A., Rammelt S., et al. Risk-inducing activities leading to injuries in a child and adolescent population of Germany. J Trauma. 2007 ; 62: 996-1003.
14. Agran PF, Winn D., Anderson C., Trent R., Walton-Haynes L. Rates of pediatric and adolescent injuries by year of age. Pediatrics. 2001 ; 108: E45.
15. Akcan R., Hilal A., Gulmen MK, Cekin N. Childhood deaths due to electrocution in Adana, Turkey. Acta Paediatr. 2007 ; 96: 443-445.
16. FDA Drug Advisory. http://www.fda.gov/cder/drug/advisory/fentanyl.html. Accessed November 25, 2007.
17. Agran PF, Anderson C., Winn D., Trent R., Walton-Haynes L., Thayer S. Rates of pediatric injuries by 3-month intervals for children 0 to 3 years of age. Pediatrics. 2003 ; 111: e683-692.
18. Lopez FA ADHD: new pharmacological treatments on the horizon. J Dev Behav Pediatr. 2006 ; 27: 410-416.
19. Barrett SP, Darredeau C., Bordy LE, Pihl RO Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry. 2005 ; 50: 457-461.
20. Poulin C. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction. 2007 ; 102: 740-751.
21. Haroz R., Greenberg MI New drugs of abuse in North America. Clin Chem Lab Med. 2006 ; 26: 147-164.